| Literature DB >> 27065015 |
Ning Li1,2, Bing Liu2, Chengguang Sui1, Youhong Jiang1.
Abstract
As a highly conserved signaling pathway, Wnt/β-catenin signal transduction pathway plays an important role in many processes. Either in the occurrence or development of tumor, activation of this pathway takes an important place. APC inhibits Wnt/β-catenin pathway to regulate cell proliferation and differentiation. This study aimed to investigate the function of cancer suppressor gene. PCR amplification and sequencing method was used to analyze APC mutations of human clinical specimens. The pathological specimens were collected for PCR and clear electrophoretic bands were obtained after electrophoresis. The gene sequence obtained after purification and sequencing analysis was compared with the known APC gene sequence (NM_000038.5). Base mutations at APC 1543 (T → C), APC-4564 (G → A), APC-5353 (T → G), APC-5550 (T → A) and APC-5969 (G → A) locus existed in 22 (27.5 %), 12 (15 %), 5 (6.25 %), 13 (16.25 %) and 12 patients (15 %), respectively. Gene mutations existed in ameloblastoma, and the mutation loci were 1543 locus (T → C), 4564 locus (G → A), 5353 locus (T → G), 5550 locus (T → A) and 5969 locus (G → A) 15 %, respectively. APC mutation plays a certain role in monitoring the tumor malignant degree as it may indicate the transition process of ameloblastoma malignant phenotype.Entities:
Keywords: APC; Ameloblastoma; Mutation; Wnt/β-catenin
Year: 2016 PMID: 27065015 PMCID: PMC4786515 DOI: 10.1186/s40064-016-1904-3
Source DB: PubMed Journal: Springerplus ISSN: 2193-1801
Fig. 1β-catenin is expressed in the normal oral mucous membrane, with no aberrant expression in cytoplasm and nucleus, by SP ×20
Fig. 2β-catenin is aberrant expressed in cytoplasm of ABs, by SP ×20
Fig. 3β-catenin is aberrant expressed in nucleus of ABs (arrow), by SP ×40
Fig. 4Agarose electrophoresis and sequencing results for specimen mutation. a 0: DL2000; 1–30: sample 1–30, b 0: DL2000; 1–5: AX1-1–5; 6: AX1-3; 7–11: AX1-6–10; 12–16: AX2-1–5; 17: AX2-67; 18–20: AX2-8–10; 21: DDR1-56; 22: DDR1-4; 23: DDR2-4; 23: DDR2-17; 25: AXT1-3; 26: AXT3-2; 27: AXT2-3; 28: CTN, c base mutation at 37 codon: serine → cysteine, d serine → asparagine; base mutation at 496 codon: alanine → threonine in sample 13, e base mutation at 603 codon: alanine → proline, f base mutation at 738 codon: serine → phenylalanine, g base mutation at 50 codon: proline → serine
Detection and analyses results of APC locus mutation
| Mutation locus | Number of cases | Mutation | Mutation rate (%) |
|---|---|---|---|
| 1543 | 22 | T → C | 27.5 |
| 4564 | 12 | G → A | 15 |
| 5353 | 5 | T → G | 6.25 |
| 5550 | 13 | T → A | 16.25 |
| 5969 | 12 | G → A | 15 |
Base changes with tumor subtypes
| Gene | Sample (n) | Age | Gender | Location | Type | Pathological type | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <50 | >50 | M | F | Upper | Lower | Other | Primary | Recurrent | Malignant | Follicular | Acanthomatous | Plexiform | Desmoplastic | Peripheral | Mixed | Single cystic | ||
| 1543 | 22 | 10 | 12 | 14 | 8 | 2 | 20 | 16 | 6 | 12 | 3 | 4 | 1 | 3 | 1 | |||
| 4564 | 12 | 6 | 6 | 7 | 5 | 1 | 10 | 1 | 11 | 1 | 8 | 1 | 1 | 1 | 1 | |||
| 5353 | 5 | 3 | 2 | 3 | 2 | 1 | 4 | 4 | 1 | 4 | 1 | |||||||
| 5550 | 13 | 7 | 6 | 8 | 5 | 12 | 1 | 11 | 2 | 9 | 3 | 2 | ||||||
| 5969 | 12 | 5 | 7 | 5 | 7 | 1 | 11 | 10 | 2 | 9 | 1 | 1 | 1 | |||||
Notes: M: male; F: female
Detection results of APC methylation
| APC | 2 | 3 | 4 | 5 | 8 | 9 | 10 | 15 | 17 | 21 |
|---|---|---|---|---|---|---|---|---|---|---|
| CPG1 | U | U | U | U | U | U | U | U | U | U |
| CPG2 | U | U | U | U | U | U | U | U | U | U |
| CPG3 | U | U | U | U | U | U | U | U | U | U |
| CPG4 | U | U | U | U | U | U | U | U | U | U |
| CPG5 | U | U | U | U | U | U | U | U | U | U |
| CPG6 | U | U | U | U | U | U | U | U | U | U |
| CPG7 | U | U | U | U | U | U | U | U | U | U |
| CPG8 | U | U | U | U | U | U | U | U | U | U |
| CPG9 | U | U | U | U | U | U | U | U | U | U |
| CPG10 | U | U | U | U | U | U | U | U | U | U |
| CPG11 | U | U | U | U | U | U | U | U | U | U |
| CPG12 | U | U | U | U | U | U | U | U | U | U |
| CPG13 | U | U | U | U | U | U | U | U | U | U |
| CPG14 | U | U | U | U | U | U | U | U | U | U |
| CPG15 | U | U | U | U | U | U | U | U | U | U |
| CPG16 | U | U | U | U | U | U | U | U | U | U |
| CPG17 | U | U | U | U | U | U | U | U | U | U |
| CPG18 | U | U | U | U | U | U | U | U | U | U |
| CPG19 | U | U | U | U | U | U | U | U | U | U |
| CPG20 | U | U | U | U | U | U | U | U | U | U |
| CPG21 | U | U | U | U | U | U | U | U | U | U |
| CPG22 | U | U | U | U | U | U | U | U | U | U |
Patient demographics
| Sample | Age | Gender | Location | Primary/recurrent/malignant | Pathological type |
|---|---|---|---|---|---|
| 1 | 26 | Male | Lower | Primary | Single cystic |
| 2 | 81 | Male | Lower | Recurrent | Follicular |
| 3 | 54 | Female | Parapharyngeal space | Primary | Peripheral |
| 4 | 34 | Male | Lower | Primary | Follicular |
| 5 | 53 | Female | Lower | Recurrent | Follicular |
| 6 | 46 | Male | Lower | Recurrent | Acanthsomatous |
| 7 | 40 | Female | Lower | Primary | Follicular |
| 8 | 69 | Female | Cheek | Recurrent | Peripheral |
| 9 | 21 | Male | Lower | Primary | Plexiform |
| 10 | 59 | Male | Lower | Primary | Follicular |
| 11 | 45 | Male | Lower | Primary | Follicular |
| 12 | 43 | Female | Upper | Primary | Follicular |
| 13 | 59 | Female | Gingiva | Recurrent | Peripheral |
| 14 | 46 | Male | Lower | Primary | Plexiform + Follicular |
| 15 | 40 | Female | Lower | Recurrent | Follicular |
| 16 | 72 | Male | Lower | Primary | Desmoplastic |
| 17 | 31 | Male | Lower | Recurrent | Follicular |
| 18 | 16 | Female | Lower | Recurrent | Plexiform |
| 19 | 45 | Female | Lower | Primary | Follicular |
| 20 | 40 | Female | Upper | Recurrent | Follicular |
| 21 | 56 | Male | Lower | Recurrent | Follicular |
| 22 | 18 | Male | Lower | Primary | Follicular |
| 23 | 21 | Female | Lower | Primary | Follicular |
| 24 | 22 | Female | Lower | Primary | Follicular |
| 25 | 44 | Male | Lower | Recurrent | Basal |
| 26 | 59 | Female | Lower | Primary | Acanthomatous |
| 27 | 68 | Male | Lower | Malignant | Basal |
| 28 | 26 | Male | Lower | Primary | Basal |
| 29 | 58 | Male | Lower | Primary | Plexiform |
| 30 | 40 | Female | Upper | Malignant | Plexiform |
Primers of APC exon
| APC exon | Primer | Sequence | Gragment (bp) | Temperature (°C) | Time (sec) |
|---|---|---|---|---|---|
| 1 | APC-1F | TTTTGTTTCCTTTACCCCTTTC | 450 | 55 | 30 |
| APC-1R | CCATTGGAGTTTTACACTTATTTTC | ||||
| 2 | APC-2F | AATCACCATTATCTCAAAATATCAC | 411 | 55 | 30 |
| APC-2R | GCTAACATACCAAGAAAACTGAT | ||||
| 3 | APC-3F | AACACACTCCTTATTTTTACCCT | 516 | 55 | 30 |
| APC-3R | ATGCAAAATGCTCTAAGTGTTAG | ||||
| 4 | APC-4F | TAACAACTGATGTAAGTATTGCTCT | 470 | 57 | 30 |
| APC-4R | TAGTTGCCTAGTTGAACCCTG | ||||
| 5 | APC-5F | ATTGATACTTTTTTATTATTTGTGG | 400 | 57 | 30 |
| APC-5R | CATCTAACTCTGTCTCTCCCTTA | ||||
| 6 | APC-6F | TGAGAATGATTTGACATAACCCTGA | 227 | 57 | 30 |
| APC-6R | ATACCCACAAACAAGAAAGGCA | ||||
| 7 | APC-7F | ACTTCACTTTCCCCTTACCGAG | 400 | 57 | 30 |
| APC-7R | TCTTAGAACCATCTTGCTTCATACT | ||||
| 8 | APC-8F | ATTCCTTCAATGCTTTTCATCA | 400 | 57 | 30 |
| APC-8R | CCAGGGTTTGTAATCTTCTGTTA | ||||
| 9 | APC-9F | TTGTTTCTAAACTCATTTGGCC | 525 | 55 | 30 |
| APC-9R | TGATATGAATTTTCTCCTCTTAGTC | ||||
| 10 | APC-10F | TTGTAGTATTTATTCATCCTTTCAG | 471 | 55 | 30 |
| APC-10R | AGGGTAGCAGTTTCTGTGATTC | ||||
| 11 | APC-11F | TGGCATAAAATGGAATAATTGTCAG | 500 | 55 | 30 |
| APC-11R | AGTAAAGATAAGCGAATGTGAAGCA | ||||
| 12 | APC-12F | ATTGATTCCATCCAAATAAGAGG | 470 | 55 | 30 |
| APC-12R | TGAGCTGAGATTGCACAACTG | ||||
| 13 | APC-13F | AGAAGGTCTTGAACTCCTGGT | 400 | 55 | 30 |
| APC-13R | AGAAATTAGGAAATCTCATGGC | ||||
| 14 | APC-14F | AGTGAGGGACGGGCAATAGGATA | 576 | 55 | 30 |
| APC-14R | ACCTATGGGCTACACCTCTCAACTA | ||||
| 15 | APC15-1F | TATGCCTTTTGTCTTCTATCCTTTT | 1282 | 57 | 45 |
| 16 | APC15-1R | GTCTTGCCCATCTTTCATTCTGT | |||
| APC15-11R | AACCATCAAGAGTGCCTCCCAAAA |
Primer sequence detection of promoter region with APC methylation
| Gene | Primer | Fragment size | |
|---|---|---|---|
| APC | F | AGTGTGTGTAGAAGGATTTATTAATTGGG | 380 |
| R | CAACCAACAACAATACCTAAAAACAACAT | ||